1. East China Pharmaceutical Co., Ltd. (stock code: 000963) was established in 1993, headquartered in Hangzhou, Zhejiang Province, and listed on the Shenzhen Stock Exchange in February of 1999. After more than 20 years of development, the company's business covers the whole pharmaceutical industry chain, with the pharmaceutical industry as the leading factor, and at the same time, it has expanded the business of pharmaceutical commerce, medical beauty industry and industrial microbiology, and has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical R&D, production and circulation.
2. Unocom Central Institute of Medicine is a first-class high-tech drug incubation base in China, with R&D centers and clinical centers in California, Lastun, Texas and New Jersey. The annual R&D investment was 3.5 billion yuan, and the compound annual growth rate of R&D investment reached 36.76% from 20 18 to 20021year. At present, a research and development team of 2,000 people has been established, including thousands of highly educated talents such as masters and doctors. A complete research and development system has been established in innovative drugs, generic drugs, biological drugs and antibody drugs, ranking among the first-class research and development pharmaceutical enterprises in China.